Budesonide/formoterol via <scp>T</scp>urbuhaler® versus formoterol via <scp>T</scp>urbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase <scp>III</scp> multinational study results

Budesonide/formoterol 160/4.5 μg two inhalations twice daily was effective and well tolerated in patients with moderate to severe COPD, offering benefits over formoterol alone in terms of improved lung function and reduced risk of exacerbation.